CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-29 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-05-29 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +402,500 | 402,500 | ||
| 2026-05-29 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +402,500 | 402,500 | ||
| 2026-05-29 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-01-23 | Lanfear Dennis M President & CEO | Grant or award | +375,000 | 1,048,235 | ||
| 2026-01-23 | Lanfear Dennis M President & CEO | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 | ||
| 2026-01-22 | McMichael Bryan J Chief Financial Officer | Grant or award | +112,500 | 133,736 | ||
| 2026-01-22 | McMichael Bryan J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2026-01-20 | McMichael Bryan J Chief Financial Officer | Shares withheld for taxes | −1,715 | $1.55 | $3K | 21,236 |
| 2026-01-20 | Lanfear Dennis M President & CEO | Shares withheld for taxes | −11,839 | $1.55 | $18K | 673,235 |
| 2025-06-12 | O'Donnell-Tormey Jill Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Newcomer Lee Nisley Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Wahlstrom Mats Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Ryan Michael Lee Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Karachun Rita A Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Erbez Georgia Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Newton Charles W. Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-06-12 | Satvat Ali J. Director | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2025-05-23 | Wahlstrom Mats Director | Sale | −99,988 | $0.74 | $74K | 0 |
| 2025-05-07 | McMichael Bryan J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 |
Page 3 of 39 · 768 trades